Literature DB >> 19156172

Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.

Maria Lisa Dentici1, Anna Sarkozy, Francesca Pantaleoni, Claudio Carta, Francesca Lepri, Rosangela Ferese, Viviana Cordeddu, Simone Martinelli, Silvana Briuglia, Maria Cristina Digilio, Giuseppe Zampino, Marco Tartaglia, Bruno Dallapiccola.   

Abstract

Cardio-facio-cutaneous syndrome (CFCS) is a rare disease characterized by mental retardation, facial dysmorphisms, ectodermal abnormalities, heart defects and developmental delay. CFCS is genetically heterogeneous and mutations in the KRAS, BRAF, MAP2K1 (MEK1) and MAP2K2 (MEK2) genes, encoding for components of the RAS-mitogen activated protein kinase (MAPK) signaling pathway, have been identified in up to 90% of cases. Here we screened a cohort of 33 individuals with CFCS for MEK1 and MEK2 gene mutations to further explore their molecular spectrum in this disorder, and to analyze genotype-phenotype correlations. Three MEK1 and two MEK2 mutations were detected in six patients. Two missense MEK1 (L42F and Y130H) changes and one in-frame MEK2 (K63_E66del) deletion had not been reported earlier. All mutations were localized within exon 2 or 3. Together with the available records, the present data document that MEK1 mutations are relatively more frequent than those in MEK2, with exons 2 and 3 being mutational hot spots in both genes. Mutational analysis of the affected MEK1 and MEK2 exons did not reveal occurrence of mutations among 75 patients with Noonan syndrome, confirming the low prevalence of MEK gene defects in this disorder. Clinical review of known individuals with MEK1/MEK2 mutations suggests that these patients show dysmorphic features, ectodermal abnormalities and cognitive deficit similar to what was observed in BRAF-mutated patients and in the general CFCS population. Conversely, congenital heart defects, particularly mitral valve and septal defects, and ocular anomalies seem to be less frequent among MEK1/MEK2 mutation-positive patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19156172      PMCID: PMC2947095          DOI: 10.1038/ejhg.2008.256

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  27 in total

Review 1.  The MEK/ERK cascade: from signaling specificity to diverse functions.

Authors:  Yoav D Shaul; Rony Seger
Journal:  Biochim Biophys Acta       Date:  2006-10-19

Review 2.  Hyperactive Ras in developmental disorders and cancer.

Authors:  Suzanne Schubbert; Kevin Shannon; Gideon Bollag
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

3.  Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene.

Authors:  Yoshio Makita; Yoko Narumi; Makoto Yoshida; Tetsuya Niihori; Shigeo Kure; Kenji Fujieda; Yoichi Matsubara; Yoko Aoki
Journal:  J Pediatr Hematol Oncol       Date:  2007-05       Impact factor: 1.289

4.  Hepatoblastoma and heart transplantation in a patient with cardio-facio-cutaneous syndrome.

Authors:  Mohamad M Al-Rahawan; Deborah J Chute; Katia Sol-Church; Karen W Gripp; Deborah L Stabley; Nancy L McDaniel; William G Wilson; Peter E Waldron
Journal:  Am J Med Genet A       Date:  2007-07-01       Impact factor: 2.802

5.  Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.

Authors:  Yoko Narumi; Yoko Aoki; Tetsuya Niihori; Giovanni Neri; Hélène Cavé; Alain Verloes; Caroline Nava; Maria Ines Kavamura; Nobuhiko Okamoto; Kenji Kurosawa; Raoul C M Hennekam; Louise C Wilson; Gabriele Gillessen-Kaesbach; Dagmar Wieczorek; Pablo Lapunzina; Hirofumi Ohashi; Yoshio Makita; Ikuko Kondo; Shigeru Tsuchiya; Etsuro Ito; Kiyoko Sameshima; Kumi Kato; Shigeo Kure; Yoichi Matsubara
Journal:  Am J Med Genet A       Date:  2007-04-15       Impact factor: 2.802

6.  Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome.

Authors:  Karen W Gripp; Angela E Lin; Linda Nicholson; William Allen; Andrea Cramer; Kenneth L Jones; Wendy Kutz; Dawn Peck; Michael A Rebolledo; Patricia G Wheeler; William Wilson; Mohamad M Al-Rahawan; Deborah L Stabley; Katia Sol-Church
Journal:  Am J Med Genet A       Date:  2007-07-01       Impact factor: 2.802

7.  Germline gain-of-function mutations in RAF1 cause Noonan syndrome.

Authors:  M Abdur Razzaque; Tsutomu Nishizawa; Yuta Komoike; Hisato Yagi; Michiko Furutani; Ryunosuke Amo; Mitsuhiro Kamisago; Kazuo Momma; Hiroshi Katayama; Masao Nakagawa; Yuko Fujiwara; Masaki Matsushima; Katsumi Mizuno; Mika Tokuyama; Hamao Hirota; Jun Muneuchi; Toru Higashinakagawa; Rumiko Matsuoka
Journal:  Nat Genet       Date:  2007-07-01       Impact factor: 38.330

8.  Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype.

Authors:  Claudio Carta; Francesca Pantaleoni; Gianfranco Bocchinfuso; Lorenzo Stella; Isabella Vasta; Anna Sarkozy; Cristina Digilio; Antonio Palleschi; Antonio Pizzuti; Paola Grammatico; Giuseppe Zampino; Bruno Dallapiccola; Bruce D Gelb; Marco Tartaglia
Journal:  Am J Hum Genet       Date:  2006-05-01       Impact factor: 11.025

9.  Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.

Authors:  Bhaswati Pandit; Anna Sarkozy; Len A Pennacchio; Claudio Carta; Kimihiko Oishi; Simone Martinelli; Edgar A Pogna; Wendy Schackwitz; Anna Ustaszewska; Andrew Landstrom; J Martijn Bos; Steve R Ommen; Giorgia Esposito; Francesca Lepri; Christian Faul; Peter Mundel; Juan P López Siguero; Romano Tenconi; Angelo Selicorni; Cesare Rossi; Laura Mazzanti; Isabella Torrente; Bruno Marino; Maria C Digilio; Giuseppe Zampino; Michael J Ackerman; Bruno Dallapiccola; Marco Tartaglia; Bruce D Gelb
Journal:  Nat Genet       Date:  2007-07-01       Impact factor: 38.330

10.  Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome.

Authors:  Marco Tartaglia; Len A Pennacchio; Chen Zhao; Kamlesh K Yadav; Valentina Fodale; Anna Sarkozy; Bhaswati Pandit; Kimihiko Oishi; Simone Martinelli; Wendy Schackwitz; Anna Ustaszewska; Joel Martin; James Bristow; Claudio Carta; Francesca Lepri; Cinzia Neri; Isabella Vasta; Kate Gibson; Cynthia J Curry; Juan Pedro López Siguero; Maria Cristina Digilio; Giuseppe Zampino; Bruno Dallapiccola; Dafna Bar-Sagi; Bruce D Gelb
Journal:  Nat Genet       Date:  2006-12-13       Impact factor: 38.330

View more
  22 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

2.  In vivo severity ranking of Ras pathway mutations associated with developmental disorders.

Authors:  Granton A Jindal; Yogesh Goyal; Kei Yamaya; Alan S Futran; Iason Kountouridis; Courtney A Balgobin; Trudi Schüpbach; Rebecca D Burdine; Stanislav Y Shvartsman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-03       Impact factor: 11.205

3.  Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.

Authors:  Bradley Garman; Ioannis N Anastopoulos; Clemens Krepler; Patricia Brafford; Katrin Sproesser; Yuchao Jiang; Bradley Wubbenhorst; Ravi Amaravadi; Joseph Bennett; Marilda Beqiri; David Elder; Keith T Flaherty; Dennie T Frederick; Tara C Gangadhar; Michael Guarino; David Hoon; Giorgos Karakousis; Qin Liu; Nandita Mitra; Nicholas J Petrelli; Lynn Schuchter; Batool Shannan; Carol L Shields; Jennifer Wargo; Brandon Wenz; Melissa A Wilson; Min Xiao; Wei Xu; Xaiowei Xu; Xiangfan Yin; Nancy R Zhang; Michael A Davies; Meenhard Herlyn; Katherine L Nathanson
Journal:  Cell Rep       Date:  2017-11-14       Impact factor: 9.423

4.  Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer.

Authors:  Aphrothiti J Hanrahan; Brooke E Sylvester; Matthew T Chang; Arijh Elzein; Jianjiong Gao; Weiwei Han; Ye Liu; Dong Xu; Sizhi P Gao; Alexander N Gorelick; Alexis M Jones; Amber J Kiliti; Moriah H Nissan; Clare A Nimura; Abigail N Poteshman; Zhan Yao; Yijun Gao; Wenhuo Hu; Hannah C Wise; Elena I Gavrila; Alexander N Shoushtari; Shakuntala Tiwari; Agnes Viale; Omar Abdel-Wahab; Taha Merghoub; Michael F Berger; Neal Rosen; Barry S Taylor; David B Solit
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

Review 5.  The molecular genetics of congenital heart disease: a review of recent developments.

Authors:  Michael Wolf; Craig T Basson
Journal:  Curr Opin Cardiol       Date:  2010-05       Impact factor: 2.161

Review 6.  PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?

Authors:  Jessica Lauriol; Maria I Kontaridis
Journal:  Trends Cardiovasc Med       Date:  2011-05       Impact factor: 6.677

7.  Inference of Multisite Phosphorylation Rate Constants and Their Modulation by Pathogenic Mutations.

Authors:  Eyan Yeung; Sarah McFann; Lewis Marsh; Emilie Dufresne; Sarah Filippi; Heather A Harrington; Stanislav Y Shvartsman; Martin Wühr
Journal:  Curr Biol       Date:  2020-02-13       Impact factor: 10.834

8.  Constitutive MEK1 activation rescues anthrax lethal toxin-induced vascular effects in vivo.

Authors:  Robert E Bolcome; Joanne Chan
Journal:  Infect Immun       Date:  2010-09-20       Impact factor: 3.441

9.  Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?

Authors:  M J M Nowaczyk; B A Thompson; S Zeesman; U Moog; P A Sanchez-Lara; P L Magoulas; R E Falk; J E Hoover-Fong; D A S Batista; S M Amudhavalli; S M White; G E Graham; K A Rauen
Journal:  Clin Genet       Date:  2013-04-02       Impact factor: 4.438

10.  MEK1 mutations confer resistance to MEK and B-RAF inhibition.

Authors:  Caroline M Emery; Krishna G Vijayendran; Marie C Zipser; Allison M Sawyer; Lili Niu; Jessica J Kim; Charles Hatton; Rajiv Chopra; Patrick A Oberholzer; Maria B Karpova; Laura E MacConaill; Jianming Zhang; Nathanael S Gray; William R Sellers; Reinhard Dummer; Levi A Garraway
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.